Created Date: July 07, 2009
Description: Dr. Michael Hallek discusses treatment of high-risk Binet stage A CLL patients and their inclusion in clinical trials performed by the German CLL Study Group (DCLLSG), the controversy over the inclusion of monoclonal B-cell lymphocytosis (MBL) in the iwCLL’s revision to the National Cancer Institute–sponsored Working Group’s (NCI-WG) 1996 guidelines, and the role of splenectomy in CLL treatment.
Creator: Gerald Marti
Contributor: Michael Hallek
Series: Hallek Oral Histories
Rights: This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.